

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE GENERIC PHARMACEUTICALS PRICING
ANTITRUST LITIGATION

MDL 2724
16-md-2724

HON. CYNTHIA M. RUFÉ

THIS DOCUMENT RELATES TO:

Civil Action Nos.

ALL ALBUTEROL END-PAYER ACTIONS
ALL AMITRIPTYLINE END-PAYER ACTIONS
ALL AMITRIPTYLINE INDIRECT RESELLER ACTIONS
ALL BACLOFEN END-PAYER ACTIONS
ALL BACLOFEN INDIRECT RESELLER ACTIONS
ALL BENAZEPRIL END-PAYER ACTIONS
ALL CLOBETASOL END-PAYER ACTIONS
ALL CLOBETASOL INDIRECT RESELLER ACTIONS
ALL CLOMIPRAMINE END-PAYER ACTIONS
ALL DESONIDE END-PAYER ACTIONS
ALL DESONIDE INDIRECT RESELLER ACTIONS
ALL DIGOXIN END-PAYER ACTIONS
ALL DIGOXIN INDIRECT RESELLER ACTIONS
ALL DIVALPROEX END-PAYER ACTIONS
ALL DIVALPROEX INDIRECT RESELLER ACTIONS
ALL DOXYCYCLINE END-PAYER ACTIONS
ALL DOXYCYCLINE INDIRECT RESELLER ACTIONS
ALL ECONAZOLE END-PAYER ACTIONS
ALL FLUOCINONIDE INDIRECT RESELLER ACTIONS
ALL LIDOCAINE-PRILOCAINE END-PAYER ACTIONS
ALL LIDOCAINE-PRILOCAINE INDIRECT RESELLER ACTIONS
ALL PRAVASTATIN END-PAYER ACTIONS
ALL PROPRANOLOL END-PAYER ACTIONS
ALL PROPRANOLOL INDIRECT RESELLER ACTIONS
ALL URSODIOL END-PAYER ACTIONS
ALL URSODIOL INDIRECT RESELLER ACTIONS

16-AL-27242
16-AM-27242
16-AM-27243
16-BC-27242
16-BC-27243
16-BZ-27242
16-CB-27242
16-CB-27243
16-CM-27242
16-DS-27242
16-DS-27243
16-DG-27242
16-DG-27243
16-DV-27242
16-DV-27243
16-DX-27242
16-DX-27243
16-EC-27242
16-FL-27243
16-LD-27242
16-LD-27243
16-PV-27242
16-PP-27242
16-PP-27243
16-UR-27242
16-UR-27243

18-cv-2401

1199 SEIU NATIONAL BENEFIT FUND, et al. v.
ACTAVIS HOLDING U.S., INC., et al.

ORDER REGARDING SUMMONSES ISSUED IN CONNECTION WITH END-
PAYER AND INDIRECT RESELLER PLAINTIFFS' AMENDED COMPLAINTS

Upon the filing of the Amended Complaints in the above-captioned actions on April 26, 2019, the Clerk of Court issued Summonses where the docket did not list counsel as having entered an appearance for a Defendant, as set forth in the chart attached as Appendix A. Because of the complexity of the MDL and the number of cases and parties thereto, it appears that Summonses may have been issued in error.

AND NOW, this 28th day of May 2019, it is hereby **ORDERED** that:

1. Summonses are not required to be served upon any Defendants who already have been served or agreed to waive service and Plaintiffs have no service obligations under Federal Rule of Civil Procedure 4 as to such Summonses.
2. Counsel for Defendants who have not filed a Notice of Appearance in any case shall do so forthwith.
3. Counsel for Defendants who have filed a Notice of Appearance shall review the dockets for these cases and determine whether the appearance has been correctly associated with their clients and shall promptly notify the Clerk's Office of any previous entry of appearance that is not associated on the docket with the appropriate Defendant.

It is so **ORDERED**.

BY THE COURT:

/s/ Cynthia M. Rufe

CYNTHIA M. RUFÉ, J.

Appendix A

Actavis Holdco US, Inc. Actavis Pharma, Inc.	16-CB-27242 16-CB-27243 16-DS-27242 16-DS-27243 16-DX-27242 16-DX-27243 16-FL-27242 16-FL-27243 16-PP-27242 16-PP-27243 16-UR-27242 16-UR-27243
Aurobindo Pharma USA, Inc.	18-cv-2401
Barr Pharmaceuticals, Inc.	18-cv-2401
Dava Pharmaceuticals, LLC	18-cv-2401
Dr. Reddy's Laboratories	16-DV-27242 16-DV-27243 18-cv-2401
Fougera Pharmaceuticals, Inc.	18-cv-2401
Generics Bidco I, LLC	18-cv-2401
Heritage Pharmaceuticals, Inc.	18-cv-2401
Impax Laboratories, Inc.	16-DG-27242 16-DG-27243 16-LD-27242 16-LD-27243
Lupin Pharmaceuticals, Inc.	16-PV-27242
Mayne Pharma, Inc.	16-DX-27242
Mylan Inc. Mylan Pharmaceuticals, Inc.	16-AL-27242 16-AM-27242 16-BZ-27262 16-CM-27242 16-PP-27242 16-DX-27243 18-cv-2401

Par Pharmaceutical, Inc.	16-AM-27242 16-AM-27243 16-BC-27242 16-BC-27243 16-DG-27242 16-DG-27243 16-DV-27242 16-DV-27243 16-DX-27242 16-DX-27243 16-PP-27242 16-PP-27243 18-cv-2401
Perrigo New York, Inc.	16-CB-27242 16-CB-27243 16-DS-27243
Pliva, Inc.	18-cv-2401
Sandoz, Inc.	16-DS-27242 18-cv-2401
Teligent, Inc.	16-EC-27242
Zydus Pharmaceuticals USA Inc.	16-DV-27242 16-PV-27242